| Thao Tran, DO | |
|
4502 E. 41st Street, Tulsa, OK 74135-2512 | |
| (918) 619-4400 | |
| Not Available |
| Full Name | Thao Tran |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 9 Years |
| Location | 4502 E. 41st Street, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003203662 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 6062 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St David's Medical Center | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ipc Healthcare Services Of Texas Pllc | 3971824939 | 143 |
News Archive
Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.
Accessible and affordable healthcare is one of the topics of Healthcare Automation and Digitalization Congress.
Creatinc has launched the Bendy Pen, specifically designed to let you write from all angles: up, down and sideways. This way, bedridden patients can write while lying back and medical staff can make notes on the fly.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
› Verified 8 days ago
| Entity Name | Lonestar Hospital Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518237429 PECOS PAC ID: 6709049703 Enrollment ID: O20120530000620 |
News Archive
Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.
Accessible and affordable healthcare is one of the topics of Healthcare Automation and Digitalization Congress.
Creatinc has launched the Bendy Pen, specifically designed to let you write from all angles: up, down and sideways. This way, bedridden patients can write while lying back and medical staff can make notes on the fly.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
› Verified 8 days ago
| Entity Name | Ipc Healthcare Services Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023403011 PECOS PAC ID: 3971824939 Enrollment ID: O20150603001409 |
News Archive
Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.
Accessible and affordable healthcare is one of the topics of Healthcare Automation and Digitalization Congress.
Creatinc has launched the Bendy Pen, specifically designed to let you write from all angles: up, down and sideways. This way, bedridden patients can write while lying back and medical staff can make notes on the fly.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
› Verified 8 days ago
| Entity Name | Lonestar Pat Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811594203 PECOS PAC ID: 9335559871 Enrollment ID: O20201111002742 |
News Archive
Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.
Accessible and affordable healthcare is one of the topics of Healthcare Automation and Digitalization Congress.
Creatinc has launched the Bendy Pen, specifically designed to let you write from all angles: up, down and sideways. This way, bedridden patients can write while lying back and medical staff can make notes on the fly.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thao Tran, DO 4502 E. 41st Street, Tulsa, OK 74135-2512 Ph: () - | Thao Tran, DO 4502 E. 41st Street, Tulsa, OK 74135-2512 Ph: (918) 619-4400 |
News Archive
Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.
Accessible and affordable healthcare is one of the topics of Healthcare Automation and Digitalization Congress.
Creatinc has launched the Bendy Pen, specifically designed to let you write from all angles: up, down and sideways. This way, bedridden patients can write while lying back and medical staff can make notes on the fly.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
› Verified 8 days ago
Sarah Anne Shaw-dressler, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave Ste 100a, Tulsa, OK 74136 Phone: 918-494-8500 Fax: 918-307-5578 | |
Julia Margaret Kwon, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 1705 E 19th St Ste 302, Tulsa, OK 74104 Phone: 918-748-7585 Fax: 918-748-7539 | |
Peter Madden, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4502 E 41st St, Tulsa, OK 74135 Phone: 918-619-4400 | |
Robert Peter Aran, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 6160 S Yale Ave Ste 100, Tulsa, OK 74136 Phone: 918-497-3300 Fax: 918-497-3365 | |
Robert Dean Okada, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave, Ste 304, Tulsa, OK 74136 Phone: 918-494-5300 Fax: 918-494-5455 | |
Dr. Charles Wade Taylor, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 12697 E 51st St, Tulsa, OK 74146 Phone: 918-505-3200 Fax: 918-505-3253 |